J. Cilley

发表

Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation

A. Rademaker, L. Gordon, J. Winter, 2013, Leukemia & lymphoma.

Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?

L. Gordon, J. Winter, S. Singhal, 2004, Bone Marrow Transplantation.

Bevacizumab in the treatment of colorectal cancer

A. Benson, M. Mulcahy, J. Cilley, 2005, Expert opinion on biological therapy.

G‐CSF is not necessary to maintain over 99% dose–intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10‐year analysis

A. Rademaker, L. Gordon, J. Winter, 2007, British journal of haematology.

Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma.

J. Winter, D. Inwards, J. Cilley, 2006, Best practice & research. Clinical haematology.

Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas.

J. Winter, J. Cilley, 2006, Haematologica.

Neurologic Complications of Gastrointestinal Cancer

J. Raizer, J. Cilley, 2008 .

Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation.

J. Mehta, J. Cilley, C. Rihn, 2004, Haematologica.

Multiple myeloma presenting with high-output heart failure and improving with anti-angiogenesis therapy: two case reports and a review of the literature

O. Pikovskaya, J. Flaherty, Charles J. Davidson, 2008, Journal of medical case reports.